查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1806409

全球免疫檢測市場（按類型、技術、儀器、樣本類型、檢測模式、應用領域、最終用戶和部署方法）：未來預測（2025-2030 年）

Immunoassay Market by Type, Technology, Instruments, Sample Types, Detection Modes, Application Areas, End Users, Deployment Types - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計免疫檢測市場規模在 2024 年將達到 282.9 億美元，在 2025 年成長至 303.8 億美元，複合年成長率為 7.18 %，到 2030 年將達到 429 億美元。

主要市場統計數據
預測年份（2024年） 282.9億美元
基準年（2025年） 303.8億美元
預測年份（2030年） 429億美元
複合年成長率（%） 7.18%

技術突破和臨床需求結合，塑造卓越診斷，開啟免疫檢測創新的新時代

在快速發展的臨床診斷和生命科學領域，免疫檢測已成為彌合分子識別與可操作洞察之間差距的重要工具。這些測定利用抗體-抗原交互作用的特異性來準確檢測和定量生物標記，從而實現早期疾病檢測、個人化治療監測和全面的研究應用。技術創新與臨床需求之間的協同作用正在推動免疫檢測平台超越傳統實驗室，並促進其與數位分析和自動化的整合。因此，包括醫療保健提供者、藥物開發商和研究機構在內的相關人員正在轉向免疫檢測解決方案，以應對諸如新發感染疾病威脅、慢性病管理和藥物研發管線等複雜挑戰。

隨著新技術和策略夥伴關係重新定義未來臨床和研究前沿，免疫檢測領域正在發生變化

過去十年，在檢測化學和檢測方法的推動下，免疫檢測領域發生了翻天覆地的變化。整合化學冷光和螢光檢測的高通量平台實現了前所未有的靈敏度，能夠在疾病早期檢測出低豐度生物標記。微射流和生物感測器微型化的同步發展，促進了即時診斷部署，使免疫檢測的應用範圍擴展到核心實驗室之外。同時，多重技術的採用簡化了診斷工作流程，使其能夠同時分析多種分析物，縮短了獲得結果的時間，並節省了寶貴的樣本量。

分析 2025 年美國關稅對不同臨床檢測環境中免疫檢測供應鏈與成本結構的累積影響

2025年，美國對進口檢測試劑和儀器組件徵收新關稅，對免疫檢測供應鏈產生了重大影響。酵素、抗體和微孔盤基材的關稅上調增加了檢測開發商和檢測實驗室的採購成本。這些額外成本促使企業重新評估籌資策略，許多機構正在尋求多元化供應商網路，並探索國內生產替代方案。關稅政策也引發了關於如何為關鍵試劑的生產提供資源以減輕貿易政策波動影響的討論。

探索類型技術設備樣本類型檢測模式應用和最終用戶的細分洞察，塑造免疫檢測市場的動態

隨著免疫檢測領域不斷多元化，細分洞察揭示了多個類別中細微的促進因素和應用模式。以檢測方式來看，定性免疫檢測在快速篩檢應用中仍然很受歡迎，而定量免疫檢測在需要精確測量生物標記的臨床診斷應用中也日益普及。同時，螢光免疫分析和橫向流動化驗的創新正在迅速提高靈敏度和照護現場適用性。免疫檢測和高解析度蛋白質印跡等傳統技術在研究中發揮特殊作用。

探索免疫檢測生態系統的區域動態，分析美洲、歐洲、中東和非洲以及亞太地區的促進因素和挑戰

免疫檢測產業的區域動態受到美洲、歐洲、中東和非洲地區以及亞太地區不同法規環境、醫療保健基礎設施和研究生態系統的影響。在美洲，對尖端檢測法的強勁投資和強大的報銷框架正在推動先進化學冷光和多重檢測法的採用。學術界和產業界之間的合作網路正在加速轉化研究，並支持下一代平台的早期採用。然而，監管更新和關稅考慮因素繼續影響美國的籌資策略，而新興的拉丁美洲市場正在逐步採用標準化的檢測通訊協定。

對影響全球免疫檢測市場格局的主要企業的競爭策略和創新軌跡進行實力評估

主要企業正在採取多管齊下的策略，以保持其在免疫檢測領域的競爭優勢。現有的診斷製造商利用其廣泛的分銷網路和深厚的技術專長，不斷擴展其酵素免疫分析法 ( ELISA)產品系列。這些公司正在大力投資研發，以推出下一代檢測試劑並增強儀器自動化，從而提高通量和可重複性。同時，生物技術創新者正專注於專有抗體工程和高親和性試劑，並尋求建立策略夥伴關係，以加速其進入臨床診斷市場。

為行業領導者提供策略和營運建議，幫助他們利用新技術並克服免疫檢測開發中的監管複雜性

為了抓住新的商機，企業必須優先開發靈活的檢測平台，以便根據不斷變化的臨床需求快速客製化。投資模組化儀器和試劑組可以快速適應不同的應用領域，縮短新型生物標記的上市時間。同時，與技術提供者和學術中心建立策略聯盟可以加速先進檢測化學方法和微流體解決方案的檢驗。企業也應透過多元化供應鏈來增強韌性，包括為關鍵試劑和組件建立雙源協議，以降低貿易相關風險。

嚴謹的調查方法細節，結合定量資料合成和定性專家見解，確保全面的免疫檢測分析有效性

本報告採嚴謹的調查方法，結合量化資料整合與質性專家訪談，確保分析全面。主要研究包括與實驗室主任、試劑製造商、儀器開發商和監管機構的專家進行結構化討論，以獲得有關技術趨勢、供應鏈動態和區域市場波動的第一手見解。次要研究包括對科學出版物、專利申請、監管指南和行業白皮書的深入審查，檢驗新興的檢測方法和檢測規格。

摘要分析結果和策略要點摘要，突出全球免疫檢測領域的機會和挑戰

分析強調，免疫檢測創新正處於曲折點，受先進檢測模式、數位化整合和不斷發展的醫療保健需求的推動。微射流、生物感測器和連接複用技術方面的突破正在拓展靈敏度和通量的邊界，而策略合作和籌資策略調整則正在加速其商業化進程。貿易政策和關稅為供應鏈帶來了複雜性，促使行業參與者改進採購策略並實現在地化生產，以保持成本穩定性和營運韌性。

目錄

第1章 引言

第2章 分析方法

第3章執行摘要

第4章 市場概述

第5章市場動態

  • 快速照護現場免疫檢測透過整合數位讀出平台實現分散式 COVID-19 和流感檢測
  • 微流體免疫檢測促進腫瘤學和自體免疫疾病診斷中的高通量生物標記分析
  • 奈米粒子增強免疫檢測促進低濃度血清生物標記的超靈敏檢測，用於早期疾病篩檢
  • 在免疫檢測中使用重組抗體片段可提高批次一致性並減少臨床實驗室的交叉反應。
  • 將人工智慧演算法整合到免疫檢測數據分析中，實現即時異常檢測和報告
  • 從模擬免疫檢測過渡到利用單分子計數的數位免疫檢測，以提高研究環境中的定量準確性
  • 開發基於智慧型手機量化的橫向流動免疫檢測測定法，用於家庭監測慢性疾病生物標記
  • 擴展基於免疫檢測的伴隨診斷，以指導個性化腫瘤治療方法中的標靶治療選擇
  • 免疫檢測檢驗指南的監管趨同和協調加快了全球產品核可和市場准入時間
  • 實施自動化高通量免疫檢測工作站，以簡化大型臨床實驗室的血清和血漿樣本處理

第6章 市場洞察

  • 波特五力分析
  • PESTEL分析

第7章：美國關稅的累積影響（2025年）

第 8 章免疫檢測市場：依類型

  • 定性免疫檢測
  • 定量免疫檢測

第9章免疫檢測市場：依技術

  • 酵素免疫分析法
  • 是酵素結合免疫吸附檢測法
  • 螢光免疫分析法
  • 橫向流動化驗
  • 免疫檢測
  • 蛋白質印跡法

第 10 章免疫檢測市場：按設備

  • 分析儀器和套件
  • 生物感測器
  • 微流體設備
  • 微孔盤
  • PCR裝置
  • 試劑
    • 抗體
    • 抗原
    • 阻斷試劑
    • 緩衝液和標準品
    • 酵素
    • 基材
  • 軟體和服務

第 11 章免疫檢測市場（依樣本類型）

  • 血液樣本
  • 唾液樣本
  • 組織樣本
  • 尿液樣本

第12章免疫檢測市場（依檢測模式）

  • 化學冷光
  • 比色分析
  • 螢光測量
  • 放射性同位素

第13章免疫檢測市場（按應用領域）

  • 過敏
  • 自體免疫疾病
  • 心臟病學
  • 內分泌學
  • 感染疾病
  • 腫瘤學
  • 毒理學
    • 藥物檢測
    • 環境測試

第14章免疫檢測市場（依最終用戶）

  • 合約研究組織
  • 診斷實驗室
  • 醫院和診所
  • 製藥和生物技術公司
  • 研究機構

第 15 章免疫檢測市場：依部署方法

  • 實驗室檢查
  • 照護現場檢驗

第 16 章：美洲免疫檢測市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 阿根廷

第 17 章：歐洲、中東和非洲免疫檢測市場

  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 阿拉伯聯合大公國
  • 沙烏地阿拉伯
  • 南非
  • 丹麥
  • 荷蘭
  • 卡達
  • 芬蘭
  • 瑞典
  • 奈及利亞
  • 埃及
  • 土耳其
  • 以色列
  • 挪威
  • 波蘭
  • 瑞士

第 18 章：亞太免疫檢測市場

  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
  • 印尼
  • 泰國
  • 菲律賓
  • 馬來西亞
  • 新加坡
  • 越南
  • 台灣

第19章 競爭態勢

  • 市場佔有率分析（2024年）
  • FPNV定位矩陣（2024年）
  • 競爭分析
    • Abbott Laboratories
    • Agilent Technologies Inc.
    • Almac Group Limited
    • ANP Technologies, Inc.
    • Autobio Diagnostics Co., Ltd.
    • Becton, Dickinson and Company
    • Bio-Rad Laboratories, Inc.
    • Bio-Techne Corporation
    • BioLegend, Inc.
    • bioMerieux SA
    • Biosurfit SA
    • Boditech Med Inc.
    • Charles River Laboratories International, Inc.
    • Danaher Corporation
    • Diasorin SpA
    • Dynex Technologies, Inc.
    • Epitope Diagnostics Inc.
    • F. Hoffmann-La Roche Ltd.
    • Fapon Biotech Inc.
    • Gyros Protein Technologies AB by Mesa Laboratories, Inc.
    • HU Group Holdings Inc.
    • J. Mitra & Co. Pvt. Ltd.
    • Kamiya Biomedical Company
    • Koninklijke Philips NV
    • Merck KGaA
    • MiCo BioMed, Inc.
    • NanoEntek
    • Nanomix, Inc.
    • OPKO Health, Inc.
    • Promega Corporation
    • QIAGEN NV
    • Quanterix Corporation
    • QuidelOrtho Corporation
    • Randox Laboratories Ltd.
    • Revvity, Inc.（Formarly PerkinElmer, Inc.）
    • Sekisui Diagnostics, LLC
    • Shenzhen Micropoint Biotechnologies Co., Ltd.
    • Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
    • Siemens Healthineers AG
    • Sysmex Corporation
    • Tecan Trading AG
    • Thermo Fisher Scientific Inc.
    • Tosoh Corporation
    • WAK-Chemie Medical GmbH
    • Zoetis Inc.
    • Zybio Inc.

第20章 研究人工智慧

第21章 研究統計

第22章 研究聯絡人

第23章 研究報導

第24章 附錄

Product Code: MRR-43127F7279BC

The Immunoassay Market was valued at USD 28.29 billion in 2024 and is projected to grow to USD 30.38 billion in 2025, with a CAGR of 7.18%, reaching USD 42.90 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 28.29 billion
Estimated Year [2025] USD 30.38 billion
Forecast Year [2030] USD 42.90 billion
CAGR (%) 7.18%

Pioneering the New Era of Immunoassay Innovation Where Technological Breakthroughs and Clinical Demands Converge to Shape Diagnostic Excellence

In the rapidly evolving field of clinical diagnostics and life sciences, immunoassays have emerged as indispensable tools that bridge the gap between molecular recognition and actionable insights. These assays leverage the specificity of antibody-antigen interactions to deliver precise detection and quantification of biomarkers, enabling earlier disease detection, personalized therapy monitoring, and comprehensive research applications. The synergy between technological innovation and clinical demand has propelled immunoassay platforms beyond traditional laboratory settings, fostering integration with digital analytics and automation. Consequently, stakeholders across healthcare providers, pharmaceutical developers, and research institutions are engaging with immunoassay solutions to address complex challenges such as emerging infectious threats, chronic disease management, and drug discovery pipelines.

Looking ahead, the confluence of miniaturized instrumentation, advanced reagent chemistries, and AI-driven data interpretation is set to redefine performance benchmarks for sensitivity, throughput, and user experience. As market participants navigate regulatory landscapes and supply chain intricacies, strategic collaborations and cross-disciplinary research will be pivotal in unlocking next-generation immunoassay capabilities. This executive summary provides a comprehensive overview of the transformative shifts, tariff influences, segmentation insights, regional dynamics, and competitive strategies shaping the immunoassay domain. It is designed to equip decision-makers with the clarity needed to pursue innovation, optimize resource allocation, and spearhead initiatives that respond adeptly to evolving clinical and research imperatives.

As decision-makers confront an increasingly complex landscape marked by diverse regulatory requirements and economic pressures, this summary distills critical opportunities and challenges to guide effective planning and investment. By articulating key findings and strategic imperatives, it serves as a roadmap for forging resilient immunoassay strategies that deliver measurable impact across clinical, research, and commercial domains.

Charting Transformative Shifts in the Immunoassay Landscape as Emerging Technologies and Strategic Collaborations Redefine Future Clinical and Research Frontiers

Over the past decade, the immunoassay landscape has undergone seismic transformations driven by advancements in assay chemistries and detection modalities. High-throughput platforms integrating chemiluminescent and fluorometric detection have achieved unprecedented sensitivity, enabling detection of low-abundance biomarkers at earlier disease stages. Parallel developments in microfluidics and biosensor miniaturization have facilitated point-of-care deployment, expanding immunoassay accessibility beyond core labs. Meanwhile, adoption of multiplexing techniques has streamlined diagnostic workflows by enabling simultaneous analysis of multiple analytes, reducing time to results and conserving precious sample volumes.

Concurrently, the industry has witnessed a surge in strategic alliances between diagnostics developers and technology vendors seeking to co-innovate next-generation solutions. Regulatory agencies have adapted frameworks to accommodate emergent platforms while maintaining stringent quality and safety standards. The integration of data analytics and machine-learning algorithms into immunoassay systems is further enhancing predictive capabilities and enabling real-time decision support. Collectively, these shifts are recalibrating competitive dynamics, as legacy manufacturers vie with nimble biotech firms and instrumentation specialists to deliver integrated, end-to-end offerings. Furthermore, continuous monitoring of emerging biomarkers through collaborative research consortia will ensure pipeline robustness. This evolving environment requires companies to calibrate their portfolios and embrace continuous innovation as core to strategic planning.

As organizations align their strategic roadmaps with these technological and market evolutions, adopting agile development methodologies and fostering collaborative ecosystems will be essential to capitalize on new growth trajectories.

Analyzing the Cumulative Impact of United States Tariffs in 2025 on Immunoassay Supply Chains and Cost Structures Across Diverse Clinical Testing Environments

In 2025, newly imposed United States tariffs targeting imported laboratory reagents and instrumentation components have exerted a notable influence on immunoassay supply chains. The increased duties on enzymes, antibodies, and microplate substrates have elevated procurement costs for assay developers and testing laboratories. These additional expenses have prompted a strategic reevaluation of sourcing strategies, with many organizations seeking to diversify supplier networks and explore domestic manufacturing alternatives. The tariff policy has also catalyzed discussions around reshoring critical reagent production to mitigate exposure to fluctuating trade policies.

Beyond direct cost implications, the tariffs have introduced complexity into long-term planning and budgeting processes. Testing facilities have initiated collaborative agreements to negotiate volume-based discounts and lock in favorable contract terms. At the same time, equipment manufacturers are investing in localized assembly operations to offset duties on imported instrument components. This recalibration of supply chain logistics has led to incremental investments in inventory management systems and alternative distribution channels. Industry associations are convening to advocate for tariff exclusions on critical reagents to sustain research momentum and clinical testing capacity. While short-term price increases are evident, the adaptive measures being implemented by industry stakeholders signal a gradual stabilization of cost structures and resilience against future trade uncertainties.

Uncovering Segmentation Insights into How Type Technology Instruments Sample Types Detection Modes Applications and End Users Shape Immunoassay Market Dynamics

As the immunoassay sector continues to diversify, segment-specific insights reveal nuanced drivers and adoption patterns across multiple categories. In terms of assay format, qualitative immunoassays remain prevalent for rapid screening scenarios, whereas quantitative immunoassays are gaining traction in clinical diagnostics that demand precise biomarker measurement. Technological segmentation underscores the enduring dominance of enzyme immunoassays and ELISA platforms, while fluorescent immunoassay and lateral flow assay innovations are rapidly enhancing sensitivity and point-of-care applicability. Traditional techniques such as radioimmunoassay and high-resolution western blot maintain specialized roles within research contexts.

Instrumentation segmentation further highlights the critical interplay between analyzers and kits, microfluidic devices, and biosensor platforms in defining throughput and operational flexibility. Within reagents, antibodies and antigens continue to form the assay core, supplemented by blocking reagents, buffers, enzymes, and substrates that collectively fine-tune assay performance. Emerging microplates and PCR devices are extending assay versatility, while software and services are increasingly embedded to streamline data management. Sample type considerations remain pivotal, with blood and saliva samples representing the bulk of diagnostic workflows, and tissue and urine specimens addressing niche research and toxicology applications. Detection mode preferences span chemiluminescent and colorimetric readouts to fluorometric assays and radioisotopic measurements, each selected based on sensitivity and workflow requirements. Finally, application area dynamics range from allergy and cardiology to oncology and toxicology, while end users span contract research organizations, diagnostic labs, hospitals, pharmaceutical developers, and academic institutions. Laboratory tests continue to dominate deployment, though point-of-care testing is rapidly expanding its footprint.

Exploring Regional Dynamics in the Immunoassay Ecosystem by Analyzing Americas Europe Middle East Africa and Asia Pacific Drivers and Challenges

Regional dynamics in the immunoassay industry are shaped by distinct regulatory environments, healthcare infrastructure, and research ecosystems across the Americas, Europe-Middle East-Africa, and Asia-Pacific. In the Americas, robust investment in cutting-edge instrumentation and strong reimbursement frameworks have fostered widespread adoption of advanced chemiluminescent and multiplexed assays. Collaborative networks between academic institutions and industry have accelerated translational research, driving early adoption of next-gen platforms. Nonetheless, regulatory updates and tariff considerations continue to influence procurement strategies in the United States, while emerging Latin American markets are gradually embracing standardized assay protocols.

Across Europe, the Middle East, and Africa, regulatory harmonization under European directives has promoted convergence in quality standards, facilitating cross-border assay distribution. Mature healthcare markets in Western Europe sustain high demand for quantitative immunoassays in endocrinology and oncology, while the Middle East and Africa region is experiencing incremental growth driven by investments in healthcare infrastructure and localized manufacturing initiatives. Regional coordination efforts and public-private partnerships are addressing resource constraints and expanding workforce capabilities.

In Asia-Pacific, rapid population growth and rising prevalence of chronic diseases have escalated demand for scalable immunoassay solutions. Countries such as China, India, and Japan are advancing domestic reagent and instrument manufacturing, supported by government-backed research programs. Point-of-care testing platforms are gaining momentum in remote and underserved areas, bridging diagnostic gaps and enabling real-time decision making. The confluence of supportive regulatory reforms and strategic infrastructure investments positions the Asia-Pacific region as a critical growth driver for the global immunoassay landscape.

Evaluating Strengths Competitive Strategies and Innovation Trajectories of Leading Players Shaping the Global Immunoassay Market Landscape

Leading companies have adopted multifaceted strategies to maintain competitive advantage in the immunoassay sector. Established diagnostics manufacturers continue to leverage extensive distribution networks and deep technical expertise to scale their enzyme immunoassay and ELISA product portfolios. These organizations invest heavily in research and development to introduce next-generation detection chemistries and to enhance instrument automation, thus improving throughput and reproducibility. At the same time, biotechnology innovators focus on proprietary antibody engineering and high-affinity reagents, seeking to secure strategic partnerships that accelerate their entry into clinical diagnostics markets.

Instrument vendors are increasingly integrating digital connectivity and data analytics into their systems, offering modular platforms that support both chemiluminescent and fluorometric detection modes. Biosensor specialists are collaborating with academic laboratories to expand the performance envelope of lateral flow devices, aiming to address point-of-care demands in infectious disease testing. Meanwhile, software providers are building cloud-enabled data management and workflow optimization tools that enhance regulatory compliance and real-time monitoring.

Strategic acquisitions remain a prominent growth lever, with larger players absorbing niche assay developers to broaden their application coverage across autoimmune, oncology, and toxicology segments. Joint ventures focused on co-development of microfluidic immunoassays illustrate the trend toward open innovation ecosystems. The integration of end-to-end assay development services, from reagent formulation through instrument calibration and technical support, is emerging as a critical differentiator among market leaders.

Strategic and Operational Recommendations Empowering Industry Leaders to Leverage Emerging Technologies and Navigate Regulatory Complexities in Immunoassay Development

To capitalize on emerging opportunities, organizations must prioritize the development of flexible assay platforms capable of rapid customization to evolving clinical requirements. Investing in modular instrumentation and reagent kits will enable swift adaptation across diverse application areas, reducing time-to-market for novel biomarkers. Concurrently, fostering strategic alliances with technology providers and academic centers can accelerate the validation of advanced detection chemistries and microfluidic solutions. Entities should also enhance resilience by diversifying supply chains, including the establishment of dual sourcing agreements for critical reagents and components to mitigate trade-related risks.

Regulatory intelligence capabilities should be strengthened through dedicated teams that monitor evolving guidelines and expedite compliance across multiple geographies. Implementing robust digital data management systems will streamline documentation, support real-time quality control, and facilitate remote collaboration with stakeholders. Moreover, companies should explore integrated service models that bundle assay kits with training and technical support, thereby increasing customer retention and fostering long-term partnerships. Embracing predictive analytics and machine-learning algorithms to interpret complex biomarker data can unlock new insights and drive value-added services for end users. Finally, continuous investment in staff training programs and cross-functional innovation workshops will cultivate an agile organizational culture, positioning industry leaders to respond proactively to future market shifts and healthcare imperatives.

Detailing Robust Research Methodology Integrating Quantitative Data Synthesis and Qualitative Expert Insights to Ensure Comprehensive Immunoassay Analysis Validity

This report employs a rigorous research methodology combining quantitative data synthesis and qualitative expert interviews to ensure comprehensive analysis. Primary research involved structured discussions with laboratory directors, reagent manufacturers, instrument developers, and regulatory specialists, providing firsthand insights into technological trends, supply chain dynamics, and regional market variances. Secondary research encompassed a detailed review of scientific publications, patent filings, regulatory guidelines, and industry white papers, enabling validation of emerging assay formats and detection modalities.

Quantitative data points were aggregated from curated industry databases and cross-verified against publicly disclosed financial reports and customs records to ascertain procurement cost trends and tariff impacts. Proprietary algorithms were applied to harmonize data sets across geographies and segment categories, minimizing inconsistencies and ensuring data integrity. Qualitative findings were triangulated through multiple expert perspectives to capture nuanced implications of strategic partnerships, regulatory reforms, and competitive maneuvers.

Analytical frameworks such as SWOT and Porter's Five Forces were adapted to the immunoassay context to identify key market drivers and barriers. The segmentation model was validated through pilot surveys and iterative feedback loops with domain experts. Regional analyses incorporated macroeconomic indicators and healthcare expenditure metrics to contextualize adoption patterns. Together, these methods produced a robust, evidence-based foundation that underpins the strategic insights and recommendations presented throughout the executive summary.

Summarizing Key Analytical Findings and Strategic Imperatives That Underscore Opportunities and Challenges in the Global Immunoassay Domain

The analysis underscores that immunoassay innovation is at an inflection point, driven by advanced detection modalities, digital integration, and evolving healthcare demands. Technological breakthroughs in microfluidics, biosensors, and multiplexing are expanding the frontiers of sensitivity and throughput, while strategic collaborations and regulatory adaptations are fostering accelerated commercialization pathways. Trade policies and tariffs have introduced supply chain complexities, prompting industry participants to refine sourcing strategies and localize production to maintain cost stability and operational resilience.

Segmentation insights reveal that while traditional qualitative and quantitative immunoassays retain core relevance, emerging applications in oncology, infectious disease, and toxicology are catalyzing the development of specialized reagents and instruments. Regional dynamics highlight that the Americas and mature European markets continue to lead in technology adoption, whereas Asia-Pacific presents rapid growth opportunities driven by government-backed research initiatives and expanding point-of-care infrastructure. Competitive analysis shows that market leaders are differentiating through integrated service offerings, digital analytics, and targeted acquisitions to broaden their application reach.

Strategic imperatives include investing in modular assay platforms, strengthening regulatory intelligence, and leveraging predictive analytics to deliver actionable insights. The conclusion emphasizes the critical role of agility and collaboration in translating immunoassay advancements into sustainable clinical and commercial successes. By implementing these priorities, stakeholders can navigate trade uncertainties, capitalize on emerging clinical needs, and establish sustainable growth trajectories in the global immunoassay domain.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Market Sizing & Forecasting

5. Market Dynamics

  • 5.1. Rapid point-of-care immunoassays enabling decentralized COVID-19 and influenza testing with integrated digital readout platforms
  • 5.2. Multiplexed microfluidic immunoassays driving high-throughput biomarker profiling in oncology and autoimmune disorder diagnostics
  • 5.3. Nanoparticle-enhanced immunoassays boosting ultrasensitive detection of low-abundance serum biomarkers for early disease screening
  • 5.4. Adoption of recombinant antibody fragments in immunoassays improving batch consistency and reducing cross-reactivity in clinical labs
  • 5.5. Integration of artificial intelligence algorithms in immunoassay data analysis for real-time anomaly detection and reporting
  • 5.6. Transition from analog to digital immunoassays leveraging single-molecule counting for enhanced quantitative precision in research settings
  • 5.7. Development of lateral flow immunoassays with smartphone-based quantification for home monitoring of chronic disease biomarkers
  • 5.8. Expansion of immunoassay-based companion diagnostics to guide targeted therapy selection in personalized oncology treatment regimens
  • 5.9. Regulatory convergence and harmonization of immunoassay validation guidelines accelerating global product approvals and market entry timelines
  • 5.10. Implementation of automated high-throughput immunoassay workstations to streamline serum and plasma sample processing in large clinical labs

6. Market Insights

  • 6.1. Porter's Five Forces Analysis
  • 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Immunoassay Market, by Type

  • 8.1. Introduction
  • 8.2. Qualitative Immunoassays
  • 8.3. Quantitative Immunoassays

9. Immunoassay Market, by Technology

  • 9.1. Introduction
  • 9.2. Enzyme Immunoassays
  • 9.3. Enzyme-Linked Immunosorbent Assay
  • 9.4. Fluorescent Immunoassay
  • 9.5. Lateral Flow Assay
  • 9.6. Radioimmunoassay
  • 9.7. Western Blot

10. Immunoassay Market, by Instruments

  • 10.1. Introduction
  • 10.2. Analyzers & Kits
  • 10.3. Biosensors
  • 10.4. Microfluidic Devices
  • 10.5. Microplates
  • 10.6. PCR Devices
  • 10.7. Reagents
    • 10.7.1. Antibodies
    • 10.7.2. Antigens
    • 10.7.3. Blocking Reagents
    • 10.7.4. Buffers & Standards
    • 10.7.5. Enzymes
    • 10.7.6. Substrates
  • 10.8. Software & Services

11. Immunoassay Market, by Sample Types

  • 11.1. Introduction
  • 11.2. Blood Samples
  • 11.3. Saliva Samples
  • 11.4. Tissue Samples
  • 11.5. Urine Samples

12. Immunoassay Market, by Detection Modes

  • 12.1. Introduction
  • 12.2. Chemiluminescent
  • 12.3. Colorimetric
  • 12.4. Fluorometric
  • 12.5. Radioisotopic

13. Immunoassay Market, by Application Areas

  • 13.1. Introduction
  • 13.2. Allergy
  • 13.3. Autoimmune Diseases
  • 13.4. Cardiology
  • 13.5. Endocrinology
  • 13.6. Infectious Diseases
  • 13.7. Oncology
  • 13.8. Toxicology
    • 13.8.1. Drug Screening
    • 13.8.2. Environmental Testing

14. Immunoassay Market, by End Users

  • 14.1. Introduction
  • 14.2. Contract Research Organizations
  • 14.3. Diagnostic Laboratories
  • 14.4. Hospitals & Clinics
  • 14.5. Pharmaceutical & Biotechnology Companies
  • 14.6. Research Institutions

15. Immunoassay Market, by Deployment Types

  • 15.1. Introduction
  • 15.2. Laboratory Tests
  • 15.3. Point-of-care Test

16. Americas Immunoassay Market

  • 16.1. Introduction
  • 16.2. United States
  • 16.3. Canada
  • 16.4. Mexico
  • 16.5. Brazil
  • 16.6. Argentina

17. Europe, Middle East & Africa Immunoassay Market

  • 17.1. Introduction
  • 17.2. United Kingdom
  • 17.3. Germany
  • 17.4. France
  • 17.5. Russia
  • 17.6. Italy
  • 17.7. Spain
  • 17.8. United Arab Emirates
  • 17.9. Saudi Arabia
  • 17.10. South Africa
  • 17.11. Denmark
  • 17.12. Netherlands
  • 17.13. Qatar
  • 17.14. Finland
  • 17.15. Sweden
  • 17.16. Nigeria
  • 17.17. Egypt
  • 17.18. Turkey
  • 17.19. Israel
  • 17.20. Norway
  • 17.21. Poland
  • 17.22. Switzerland

18. Asia-Pacific Immunoassay Market

  • 18.1. Introduction
  • 18.2. China
  • 18.3. India
  • 18.4. Japan
  • 18.5. Australia
  • 18.6. South Korea
  • 18.7. Indonesia
  • 18.8. Thailand
  • 18.9. Philippines
  • 18.10. Malaysia
  • 18.11. Singapore
  • 18.12. Vietnam
  • 18.13. Taiwan

19. Competitive Landscape

  • 19.1. Market Share Analysis, 2024
  • 19.2. FPNV Positioning Matrix, 2024
  • 19.3. Competitive Analysis
    • 19.3.1. Abbott Laboratories
    • 19.3.2. Agilent Technologies Inc.
    • 19.3.3. Almac Group Limited
    • 19.3.4. ANP Technologies, Inc.
    • 19.3.5. Autobio Diagnostics Co., Ltd.
    • 19.3.6. Becton, Dickinson and Company
    • 19.3.7. Bio-Rad Laboratories, Inc.
    • 19.3.8. Bio-Techne Corporation
    • 19.3.9. BioLegend, Inc.
    • 19.3.10. bioMerieux S.A.
    • 19.3.11. Biosurfit SA
    • 19.3.12. Boditech Med Inc.
    • 19.3.13. Charles River Laboratories International, Inc.
    • 19.3.14. Danaher Corporation
    • 19.3.15. Diasorin S.p.A.
    • 19.3.16. Dynex Technologies, Inc.
    • 19.3.17. Epitope Diagnostics Inc.
    • 19.3.18. F. Hoffmann-La Roche Ltd.
    • 19.3.19. Fapon Biotech Inc.
    • 19.3.20. Gyros Protein Technologies AB by Mesa Laboratories, Inc.
    • 19.3.21. H.U. Group Holdings Inc.
    • 19.3.22. J. Mitra & Co. Pvt. Ltd.
    • 19.3.23. Kamiya Biomedical Company
    • 19.3.24. Koninklijke Philips N.V.
    • 19.3.25. Merck KGaA
    • 19.3.26. MiCo BioMed, Inc.
    • 19.3.27. NanoEntek
    • 19.3.28. Nanomix, Inc.
    • 19.3.29. OPKO Health, Inc.
    • 19.3.30. Promega Corporation
    • 19.3.31. QIAGEN N.V.
    • 19.3.32. Quanterix Corporation
    • 19.3.33. QuidelOrtho Corporation
    • 19.3.34. Randox Laboratories Ltd.
    • 19.3.35. Revvity, Inc. (Formarly PerkinElmer, Inc.)
    • 19.3.36. Sekisui Diagnostics, LLC
    • 19.3.37. Shenzhen Micropoint Biotechnologies Co., Ltd.
    • 19.3.38. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
    • 19.3.39. Siemens Healthineers AG
    • 19.3.40. Sysmex Corporation
    • 19.3.41. Tecan Trading AG
    • 19.3.42. Thermo Fisher Scientific Inc.
    • 19.3.43. Tosoh Corporation
    • 19.3.44. WAK-Chemie Medical GmbH
    • 19.3.45. Zoetis Inc.
    • 19.3.46. Zybio Inc.

20. ResearchAI

21. ResearchStatistics

22. ResearchContacts

23. ResearchArticles

24. Appendix

LIST OF FIGURES

  • FIGURE 1. IMMUNOASSAY MARKET RESEARCH PROCESS
  • FIGURE 2. GLOBAL IMMUNOASSAY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 3. GLOBAL IMMUNOASSAY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 4. GLOBAL IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL IMMUNOASSAY MARKET SIZE, BY TYPE, 2024 VS 2030 (%)
  • FIGURE 6. GLOBAL IMMUNOASSAY MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
  • FIGURE 8. GLOBAL IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL IMMUNOASSAY MARKET SIZE, BY INSTRUMENTS, 2024 VS 2030 (%)
  • FIGURE 10. GLOBAL IMMUNOASSAY MARKET SIZE, BY INSTRUMENTS, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL IMMUNOASSAY MARKET SIZE, BY SAMPLE TYPES, 2024 VS 2030 (%)
  • FIGURE 12. GLOBAL IMMUNOASSAY MARKET SIZE, BY SAMPLE TYPES, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL IMMUNOASSAY MARKET SIZE, BY DETECTION MODES, 2024 VS 2030 (%)
  • FIGURE 14. GLOBAL IMMUNOASSAY MARKET SIZE, BY DETECTION MODES, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 15. GLOBAL IMMUNOASSAY MARKET SIZE, BY APPLICATION AREAS, 2024 VS 2030 (%)
  • FIGURE 16. GLOBAL IMMUNOASSAY MARKET SIZE, BY APPLICATION AREAS, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 17. GLOBAL IMMUNOASSAY MARKET SIZE, BY END USERS, 2024 VS 2030 (%)
  • FIGURE 18. GLOBAL IMMUNOASSAY MARKET SIZE, BY END USERS, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 19. GLOBAL IMMUNOASSAY MARKET SIZE, BY DEPLOYMENT TYPES, 2024 VS 2030 (%)
  • FIGURE 20. GLOBAL IMMUNOASSAY MARKET SIZE, BY DEPLOYMENT TYPES, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 21. AMERICAS IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 22. AMERICAS IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 23. UNITED STATES IMMUNOASSAY MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 24. UNITED STATES IMMUNOASSAY MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 25. EUROPE, MIDDLE EAST & AFRICA IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 26. EUROPE, MIDDLE EAST & AFRICA IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 27. ASIA-PACIFIC IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 28. ASIA-PACIFIC IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 29. IMMUNOASSAY MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. IMMUNOASSAY MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 31. IMMUNOASSAY MARKET: RESEARCHAI
  • FIGURE 32. IMMUNOASSAY MARKET: RESEARCHSTATISTICS
  • FIGURE 33. IMMUNOASSAY MARKET: RESEARCHCONTACTS
  • FIGURE 34. IMMUNOASSAY MARKET: RESEARCHARTICLES

LIST OF TABLES

  • TABLE 1. IMMUNOASSAY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL IMMUNOASSAY MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL IMMUNOASSAY MARKET SIZE, 2025-2030 (USD MILLION)
  • TABLE 5. GLOBAL IMMUNOASSAY MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL IMMUNOASSAY MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 7. GLOBAL IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 9. GLOBAL IMMUNOASSAY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL IMMUNOASSAY MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 11. GLOBAL IMMUNOASSAY MARKET SIZE, BY QUALITATIVE IMMUNOASSAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL IMMUNOASSAY MARKET SIZE, BY QUALITATIVE IMMUNOASSAYS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 13. GLOBAL IMMUNOASSAY MARKET SIZE, BY QUANTITATIVE IMMUNOASSAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL IMMUNOASSAY MARKET SIZE, BY QUANTITATIVE IMMUNOASSAYS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 15. GLOBAL IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 17. GLOBAL IMMUNOASSAY MARKET SIZE, BY ENZYME IMMUNOASSAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL IMMUNOASSAY MARKET SIZE, BY ENZYME IMMUNOASSAYS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 19. GLOBAL IMMUNOASSAY MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL IMMUNOASSAY MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 21. GLOBAL IMMUNOASSAY MARKET SIZE, BY FLUORESCENT IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL IMMUNOASSAY MARKET SIZE, BY FLUORESCENT IMMUNOASSAY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 23. GLOBAL IMMUNOASSAY MARKET SIZE, BY LATERAL FLOW ASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL IMMUNOASSAY MARKET SIZE, BY LATERAL FLOW ASSAY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 25. GLOBAL IMMUNOASSAY MARKET SIZE, BY RADIOIMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL IMMUNOASSAY MARKET SIZE, BY RADIOIMMUNOASSAY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 27. GLOBAL IMMUNOASSAY MARKET SIZE, BY WESTERN BLOT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL IMMUNOASSAY MARKET SIZE, BY WESTERN BLOT, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 29. GLOBAL IMMUNOASSAY MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL IMMUNOASSAY MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
  • TABLE 31. GLOBAL IMMUNOASSAY MARKET SIZE, BY ANALYZERS & KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL IMMUNOASSAY MARKET SIZE, BY ANALYZERS & KITS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 33. GLOBAL IMMUNOASSAY MARKET SIZE, BY BIOSENSORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL IMMUNOASSAY MARKET SIZE, BY BIOSENSORS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 35. GLOBAL IMMUNOASSAY MARKET SIZE, BY MICROFLUIDIC DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL IMMUNOASSAY MARKET SIZE, BY MICROFLUIDIC DEVICES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 37. GLOBAL IMMUNOASSAY MARKET SIZE, BY MICROPLATES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL IMMUNOASSAY MARKET SIZE, BY MICROPLATES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 39. GLOBAL IMMUNOASSAY MARKET SIZE, BY PCR DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL IMMUNOASSAY MARKET SIZE, BY PCR DEVICES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 41. GLOBAL IMMUNOASSAY MARKET SIZE, BY REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL IMMUNOASSAY MARKET SIZE, BY REAGENTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 43. GLOBAL IMMUNOASSAY MARKET SIZE, BY ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL IMMUNOASSAY MARKET SIZE, BY ANTIBODIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 45. GLOBAL IMMUNOASSAY MARKET SIZE, BY ANTIGENS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL IMMUNOASSAY MARKET SIZE, BY ANTIGENS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 47. GLOBAL IMMUNOASSAY MARKET SIZE, BY BLOCKING REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL IMMUNOASSAY MARKET SIZE, BY BLOCKING REAGENTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 49. GLOBAL IMMUNOASSAY MARKET SIZE, BY BUFFERS & STANDARDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL IMMUNOASSAY MARKET SIZE, BY BUFFERS & STANDARDS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 51. GLOBAL IMMUNOASSAY MARKET SIZE, BY ENZYMES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL IMMUNOASSAY MARKET SIZE, BY ENZYMES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 53. GLOBAL IMMUNOASSAY MARKET SIZE, BY SUBSTRATES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL IMMUNOASSAY MARKET SIZE, BY SUBSTRATES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 55. GLOBAL IMMUNOASSAY MARKET SIZE, BY REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL IMMUNOASSAY MARKET SIZE, BY REAGENTS, 2025-2030 (USD MILLION)
  • TABLE 57. GLOBAL IMMUNOASSAY MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL IMMUNOASSAY MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 59. GLOBAL IMMUNOASSAY MARKET SIZE, BY SAMPLE TYPES, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL IMMUNOASSAY MARKET SIZE, BY SAMPLE TYPES, 2025-2030 (USD MILLION)
  • TABLE 61. GLOBAL IMMUNOASSAY MARKET SIZE, BY BLOOD SAMPLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL IMMUNOASSAY MARKET SIZE, BY BLOOD SAMPLES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 63. GLOBAL IMMUNOASSAY MARKET SIZE, BY SALIVA SAMPLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL IMMUNOASSAY MARKET SIZE, BY SALIVA SAMPLES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 65. GLOBAL IMMUNOASSAY MARKET SIZE, BY TISSUE SAMPLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL IMMUNOASSAY MARKET SIZE, BY TISSUE SAMPLES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 67. GLOBAL IMMUNOASSAY MARKET SIZE, BY URINE SAMPLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL IMMUNOASSAY MARKET SIZE, BY URINE SAMPLES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 69. GLOBAL IMMUNOASSAY MARKET SIZE, BY DETECTION MODES, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL IMMUNOASSAY MARKET SIZE, BY DETECTION MODES, 2025-2030 (USD MILLION)
  • TABLE 71. GLOBAL IMMUNOASSAY MARKET SIZE, BY CHEMILUMINESCENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL IMMUNOASSAY MARKET SIZE, BY CHEMILUMINESCENT, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 73. GLOBAL IMMUNOASSAY MARKET SIZE, BY COLORIMETRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL IMMUNOASSAY MARKET SIZE, BY COLORIMETRIC, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 75. GLOBAL IMMUNOASSAY MARKET SIZE, BY FLUOROMETRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL IMMUNOASSAY MARKET SIZE, BY FLUOROMETRIC, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 77. GLOBAL IMMUNOASSAY MARKET SIZE, BY RADIOISOTOPIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL IMMUNOASSAY MARKET SIZE, BY RADIOISOTOPIC, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 79. GLOBAL IMMUNOASSAY MARKET SIZE, BY APPLICATION AREAS, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL IMMUNOASSAY MARKET SIZE, BY APPLICATION AREAS, 2025-2030 (USD MILLION)
  • TABLE 81. GLOBAL IMMUNOASSAY MARKET SIZE, BY ALLERGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL IMMUNOASSAY MARKET SIZE, BY ALLERGY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 83. GLOBAL IMMUNOASSAY MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL IMMUNOASSAY MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 85. GLOBAL IMMUNOASSAY MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL IMMUNOASSAY MARKET SIZE, BY CARDIOLOGY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 87. GLOBAL IMMUNOASSAY MARKET SIZE, BY ENDOCRINOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL IMMUNOASSAY MARKET SIZE, BY ENDOCRINOLOGY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 89. GLOBAL IMMUNOASSAY MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL IMMUNOASSAY MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 91. GLOBAL IMMUNOASSAY MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL IMMUNOASSAY MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 93. GLOBAL IMMUNOASSAY MARKET SIZE, BY TOXICOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL IMMUNOASSAY MARKET SIZE, BY TOXICOLOGY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 95. GLOBAL IMMUNOASSAY MARKET SIZE, BY DRUG SCREENING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL IMMUNOASSAY MARKET SIZE, BY DRUG SCREENING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 97. GLOBAL IMMUNOASSAY MARKET SIZE, BY ENVIRONMENTAL TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL IMMUNOASSAY MARKET SIZE, BY ENVIRONMENTAL TESTING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 99. GLOBAL IMMUNOASSAY MARKET SIZE, BY TOXICOLOGY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL IMMUNOASSAY MARKET SIZE, BY TOXICOLOGY, 2025-2030 (USD MILLION)
  • TABLE 101. GLOBAL IMMUNOASSAY MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL IMMUNOASSAY MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 103. GLOBAL IMMUNOASSAY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL IMMUNOASSAY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 105. GLOBAL IMMUNOASSAY MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL IMMUNOASSAY MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 107. GLOBAL IMMUNOASSAY MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL IMMUNOASSAY MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 109. GLOBAL IMMUNOASSAY MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL IMMUNOASSAY MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 111. GLOBAL IMMUNOASSAY MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL IMMUNOASSAY MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 113. GLOBAL IMMUNOASSAY MARKET SIZE, BY DEPLOYMENT TYPES, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL IMMUNOASSAY MARKET SIZE, BY DEPLOYMENT TYPES, 2025-2030 (USD MILLION)
  • TABLE 115. GLOBAL IMMUNOASSAY MARKET SIZE, BY LABORATORY TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL IMMUNOASSAY MARKET SIZE, BY LABORATORY TESTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 117. GLOBAL IMMUNOASSAY MARKET SIZE, BY POINT-OF-CARE TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL IMMUNOASSAY MARKET SIZE, BY POINT-OF-CARE TEST, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 119. AMERICAS IMMUNOASSAY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 120. AMERICAS IMMUNOASSAY MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 121. AMERICAS IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 122. AMERICAS IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 123. AMERICAS IMMUNOASSAY MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 124. AMERICAS IMMUNOASSAY MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
  • TABLE 125. AMERICAS IMMUNOASSAY MARKET SIZE, BY REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 126. AMERICAS IMMUNOASSAY MARKET SIZE, BY REAGENTS, 2025-2030 (USD MILLION)
  • TABLE 127. AMERICAS IMMUNOASSAY MARKET SIZE, BY SAMPLE TYPES, 2018-2024 (USD MILLION)
  • TABLE 128. AMERICAS IMMUNOASSAY MARKET SIZE, BY SAMPLE TYPES, 2025-2030 (USD MILLION)
  • TABLE 129. AMERICAS IMMUNOASSAY MARKET SIZE, BY DETECTION MODES, 2018-2024 (USD MILLION)
  • TABLE 130. AMERICAS IMMUNOASSAY MARKET SIZE, BY DETECTION MODES, 2025-2030 (USD MILLION)
  • TABLE 131. AMERICAS IMMUNOASSAY MARKET SIZE, BY APPLICATION AREAS, 2018-2024 (USD MILLION)
  • TABLE 132. AMERICAS IMMUNOASSAY MARKET SIZE, BY APPLICATION AREAS, 2025-2030 (USD MILLION)
  • TABLE 133. AMERICAS IMMUNOASSAY MARKET SIZE, BY TOXICOLOGY, 2018-2024 (USD MILLION)
  • TABLE 134. AMERICAS IMMUNOASSAY MARKET SIZE, BY TOXICOLOGY, 2025-2030 (USD MILLION)
  • TABLE 135. AMERICAS IMMUNOASSAY MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 136. AMERICAS IMMUNOASSAY MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 137. AMERICAS IMMUNOASSAY MARKET SIZE, BY DEPLOYMENT TYPES, 2018-2024 (USD MILLION)
  • TABLE 138. AMERICAS IMMUNOASSAY MARKET SIZE, BY DEPLOYMENT TYPES, 2025-2030 (USD MILLION)
  • TABLE 139. AMERICAS IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. AMERICAS IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 141. UNITED STATES IMMUNOASSAY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 142. UNITED STATES IMMUNOASSAY MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 143. UNITED STATES IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 144. UNITED STATES IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 145. UNITED STATES IMMUNOASSAY MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 146. UNITED STATES IMMUNOASSAY MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
  • TABLE 147. UNITED STATES IMMUNOASSAY MARKET SIZE, BY REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 148. UNITED STATES IMMUNOASSAY MARKET SIZE, BY REAGENTS, 2025-2030 (USD MILLION)
  • TABLE 149. UNITED STATES IMMUNOASSAY MARKET SIZE, BY SAMPLE TYPES, 2018-2024 (USD MILLION)
  • TABLE 150. UNITED STATES IMMUNOASSAY MARKET SIZE, BY SAMPLE TYPES, 2025-2030 (USD MILLION)
  • TABLE 151. UNITED STATES IMMUNOASSAY MARKET SIZE, BY DETECTION MODES, 2018-2024 (USD MILLION)
  • TABLE 152. UNITED STATES IMMUNOASSAY MARKET SIZE, BY DETECTION MODES, 2025-2030 (USD MILLION)
  • TABLE 153. UNITED STATES IMMUNOASSAY MARKET SIZE, BY APPLICATION AREAS, 2018-2024 (USD MILLION)
  • TABLE 154. UNITED STATES IMMUNOASSAY MARKET SIZE, BY APPLICATION AREAS, 2025-2030 (USD MILLION)
  • TABLE 155. UNITED STATES IMMUNOASSAY MARKET SIZE, BY TOXICOLOGY, 2018-2024 (USD MILLION)
  • TABLE 156. UNITED STATES IMMUNOASSAY MARKET SIZE, BY TOXICOLOGY, 2025-2030 (USD MILLION)
  • TABLE 157. UNITED STATES IMMUNOASSAY MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 158. UNITED STATES IMMUNOASSAY MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 159. UNITED STATES IMMUNOASSAY MARKET SIZE, BY DEPLOYMENT TYPES, 2018-2024 (USD MILLION)
  • TABLE 160. UNITED STATES IMMUNOASSAY MARKET SIZE, BY DEPLOYMENT TYPES, 2025-2030 (USD MILLION)
  • TABLE 161. UNITED STATES IMMUNOASSAY MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
  • TABLE 162. UNITED STATES IMMUNOASSAY MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
  • TABLE 163. CANADA IMMUNOASSAY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 164. CANADA IMMUNOASSAY MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 165. CANADA IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 166. CANADA IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 167. CANADA IMMUNOASSAY MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 168. CANADA IMMUNOASSAY MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
  • TABLE 169. CANADA IMMUNOASSAY MARKET SIZE, BY REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 170. CANADA IMMUNOASSAY MARKET SIZE, BY REAGENTS, 2025-2030 (USD MILLION)
  • TABLE 171. CANADA IMMUNOASSAY MARKET SIZE, BY SAMPLE TYPES, 2018-2024 (USD MILLION)
  • TABLE 172. CANADA IMMUNOASSAY MARKET SIZE, BY SAMPLE TYPES, 2025-2030 (USD MILLION)
  • TABLE 173. CANADA IMMUNOASSAY MARKET SIZE, BY DETECTION MODES, 2018-2024 (USD MILLION)
  • TABLE 174. CANADA IMMUNOASSAY MARKET SIZE, BY DETECTION MODES, 2025-2030 (USD MILLION)
  • TABLE 175. CANADA IMMUNOASSAY MARKET SIZE, BY APPLICATION AREAS, 2018-2024 (USD MILLION)
  • TABLE 176. CANADA IMMUNOASSAY MARKET SIZE, BY APPLICATION AREAS, 2025-2030 (USD MILLION)
  • TABLE 177. CANADA IMMUNOASSAY MARKET SIZE, BY TOXICOLOGY, 2018-2024 (USD MILLION)
  • TABLE 178. CANADA IMMUNOASSAY MARKET SIZE, BY TOXICOLOGY, 2025-2030 (USD MILLION)
  • TABLE 179. CANADA IMMUNOASSAY MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 180. CANADA IMMUNOASSAY MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 181. CANADA IMMUNOASSAY MARKET SIZE, BY DEPLOYMENT TYPES, 2018-2024 (USD MILLION)
  • TABLE 182. CANADA IMMUNOASSAY MARKET SIZE, BY DEPLOYMENT TYPES, 2025-2030 (USD MILLION)
  • TABLE 183. MEXICO IMMUNOASSAY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 184. MEXICO IMMUNOASSAY MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 185. MEXICO IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 186. MEXICO IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 187. MEXICO IMMUNOASSAY MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 188. MEXICO IMMUNOASSAY MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
  • TABLE 189. MEXICO IMMUNOASSAY MARKET SIZE, BY REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 190. MEXICO IMMUNOASSAY MARKET SIZE, BY REAGENTS, 2025-2030 (USD MILLION)
  • TABLE 191. MEXICO IMMUNOASSAY MARKET SIZE, BY SAMPLE TYPES, 2018-2024 (USD MILLION)
  • TABLE 192. MEXICO IMMUNOASSAY MARKET SIZE, BY SAMPLE TYPES, 2025-2030 (USD MILLION)
  • TABLE 193. MEXICO IMMUNOASSAY MARKET SIZE, BY DETECTION MODES, 2018-2024 (USD MILLION)
  • TABLE 194. MEXICO IMMUNOASSAY MARKET SIZE, BY DETECTION MODES, 2025-2030 (USD MILLION)
  • TABLE 195. MEXICO IMMUNOASSAY MARKET SIZE, BY APPLICATION AREAS, 2018-2024 (USD MILLION)
  • TABLE 196. MEXICO IMMUNOASSAY MARKET SIZE, BY APPLICATION AREAS, 2025-2030 (USD MILLION)
  • TABLE 197. MEXICO IMMUNOASSAY MARKET SIZE, BY TOXICOLOGY, 2018-2024 (USD MILLION)
  • TABLE 198. MEXICO IMMUNOASSAY MARKET SIZE, BY TOXICOLOGY, 2025-2030 (USD MILLION)
  • TABLE 199. MEXICO IMMUNOASSAY MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 200. MEXICO IMMUNOASSAY MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 201. MEXICO IMMUNOASSAY MARKET SIZE, BY DEPLOYMENT TYPES, 2018-2024 (USD MILLION)
  • TABLE 202. MEXICO IMMUNOASSAY MARKET SIZE, BY DEPLOYMENT TYPES, 2025-2030 (USD MILLION)
  • TABLE 203. BRAZIL IMMUNOASSAY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 204. BRAZIL IMMUNOASSAY MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 205. BRAZIL IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 206. BRAZIL IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 207. BRAZIL IMMUNOASSAY MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 208. BRAZIL IMMUNOASSAY MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
  • TABLE 209. BRAZIL IMMUNOASSAY MARKET SIZE, BY REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 210. BRAZIL IMMUNOASSAY MARKET SIZE, BY REAGENTS, 2025-2030 (USD MILLION)
  • TABLE 211. BRAZIL IMMUNOASSAY MARKET SIZE, BY SAMPLE TYPES, 2018-2024 (USD MILLION)
  • TABLE 212. BRAZIL IMMUNOASSAY MARKET SIZE, BY SAMPLE TYPES, 2025-2030 (USD MILLION)
  • TABLE 213. BRAZIL IMMUNOASSAY MARKET SIZE, BY DETECTION MODES, 2018-2024 (USD MILLION)
  • TABLE 214. BRAZIL IMMUNOASSAY MARKET SIZE, BY DETECTION MODES, 2025-2030 (USD MILLION)
  • TABLE 215. BRAZIL IMMUNOASSAY MARKET SIZE, BY APPLICATION AREAS, 2018-2024 (USD MILLION)
  • TABLE 216. BRAZIL IMMUNOASSAY MARKET SIZE, BY APPLICATION AREAS, 2025-2030 (USD MILLION)
  • TABLE 217. BRAZIL IMMUNOASSAY MARKET SIZE, BY TOXICOLOGY, 2018-2024 (USD MILLION)
  • TABLE 218. BRAZIL IMMUNOASSAY MARKET SIZE, BY TOXICOLOGY, 2025-2030 (USD MILLION)
  • TABLE 219. BRAZIL IMMUNOASSAY MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 220. BRAZIL IMMUNOASSAY MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 221. BRAZIL IMMUNOASSAY MARKET SIZE, BY DEPLOYMENT TYPES, 2018-2024 (USD MILLION)
  • TABLE 222. BRAZIL IMMUNOASSAY MARKET SIZE, BY DEPLOYMENT TYPES, 2025-2030 (USD MILLION)
  • TABLE 223. ARGENTINA IMMUNOASSAY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. ARGENTINA IMMUNOASSAY MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 225. ARGENTINA IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 226. ARGENTINA IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 227. ARGENTINA IMMUNOASSAY MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 228. ARGENTINA IMMUNOASSAY MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
  • TABLE 229. ARGENTINA IMMUNOASSAY MARKET SIZE, BY REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 230. ARGENTINA IMMUNOASSAY MARKET SIZE, BY REAGENTS, 2025-2030 (USD MILLION)
  • TABLE 231. ARGENTINA IMMUNOASSAY MARKET SIZE, BY SAMPLE TYPES, 2018-2024 (USD MILLION)
  • TABLE 232. ARGENTINA IMMUNOASSAY MARKET SIZE, BY SAMPLE TYPES, 2025-2030 (USD MILLION)
  • TABLE 233. ARGENTINA IMMUNOASSAY MARKET SIZE, BY DETECTION MODES, 2018-2024 (USD MILLION)
  • TABLE 234. ARGENTINA IMMUNOASSAY MARKET SIZE, BY DETECTION MODES, 2025-2030 (USD MILLION)
  • TABLE 235. ARGENTINA IMMUNOASSAY MARKET SIZE, BY APPLICATION AREAS, 2018-2024 (USD MILLION)
  • TABLE 236. ARGENTINA IMMUNOASSAY MARKET SIZE, BY APPLICATION AREAS, 2025-2030 (USD MILLION)
  • TABLE 237. ARGENTINA IMMUNOASSAY MARKET SIZE, BY TOXICOLOGY, 2018-2024 (USD MILLION)
  • TABLE 238. ARGENTINA IMMUNOASSAY MARKET SIZE, BY TOXICOLOGY, 2025-2030 (USD MILLION)
  • TABLE 239. ARGENTINA IMMUNOASSAY MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 240. ARGENTINA IMMUNOASSAY MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 241. ARGENTINA IMMUNOASSAY MARKET SIZE, BY DEPLOYMENT TYPES, 2018-2024 (USD MILLION)
  • TABLE 242. ARGENTINA IMMUNOASSAY MARKET SIZE, BY DEPLOYMENT TYPES, 2025-2030 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA IMMUNOASSAY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA IMMUNOASSAY MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA IMMUNOASSAY MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA IMMUNOASSAY MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA IMMUNOASSAY MARKET SIZE, BY REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA IMMUNOASSAY MARKET SIZE, BY REAGENTS, 2025-2030 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA IMMUNOASSAY MARKET SIZE, BY SAMPLE TYPES, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA IMMUNOASSAY MARKET SIZE, BY SAMPLE TYPES, 2025-2030 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA IMMUNOASSAY MARKET SIZE, BY DETECTION MODES, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA IMMUNOASSAY MARKET SIZE, BY DETECTION MODES, 2025-2030 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA IMMUNOASSAY MARKET SIZE, BY APPLICATION AREAS, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA IMMUNOASSAY MARKET SIZE, BY APPLICATION AREAS, 2025-2030 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA IMMUNOASSAY MARKET SIZE, BY TOXICOLOGY, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA IMMUNOASSAY MARKET SIZE, BY TOXICOLOGY, 2025-2030 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA IMMUNOASSAY MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA IMMUNOASSAY MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA IMMUNOASSAY MARKET SIZE, BY DEPLOYMENT TYPES, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA IMMUNOASSAY MARKET SIZE, BY DEPLOYMENT TYPES, 2025-2030 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 265. UNITED KINGDOM IMMUNOASSAY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 266. UNITED KINGDOM IMMUNOASSAY MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 267. UNITED KINGDOM IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 268. UNITED KINGDOM IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 269. UNITED KINGDOM IMMUNOASSAY MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 270. UNITED KINGDOM IMMUNOASSAY MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
  • TABLE 271. UNITED KINGDOM IMMUNOASSAY MARKET SIZE, BY REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 272. UNITED KINGDOM IMMUNOASSAY MARKET SIZE, BY REAGENTS, 2025-2030 (USD MILLION)
  • TABLE 273. UNITED KINGDOM IMMUNOASSAY MARKET SIZE, BY SAMPLE TYPES, 2018-2024 (USD MILLION)
  • TABLE 274. UNITED KINGDOM IMMUNOASSAY MARKET SIZE, BY SAMPLE TYPES, 2025-2030 (USD MILLION)
  • TABLE 275. UNITED KINGDOM IMMUNOASSAY MARKET SIZE, BY DETECTION MODES, 2018-2024 (USD MILLION)
  • TABLE 276. UNITED KINGDOM IMMUNOASSAY MARKET SIZE, BY DETECTION MODES, 2025-2030 (USD MILLION)
  • TABLE 277. UNITED KINGDOM IMMUNOASSAY MARKET SIZE, BY APPLICATION AREAS, 2018-2024 (USD MILLION)
  • TABLE 278. UNITED KINGDOM IMMUNOASSAY MARKET SIZE, BY APPLICATION AREAS, 2025-2030 (USD MILLION)
  • TABLE 279. UNITED KINGDOM IMMUNOASSAY MARKET SIZE, BY TOXICOLOGY, 2018-2024 (USD MILLION)
  • TABLE 280. UNITED KINGDOM IMMUNOASSAY MARKET SIZE, BY TOXICOLOGY, 2025-2030 (USD MILLION)
  • TABLE 281. UNITED KINGDOM IMMUNOASSAY MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 282. UNITED KINGDOM IMMUNOASSAY MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 283. UNITED KINGDOM IMMUNOASSAY MARKET SIZE, BY DEPLOYMENT TYPES, 2018-2024 (USD MILLION)
  • TABLE 284. UNITED KINGDOM IMMUNOASSAY MARKET SIZE, BY DEPLOYMENT TYPES, 2025-2030 (USD MILLION)
  • TABLE 285. GERMANY IMMUNOASSAY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 286. GERMANY IMMUNOASSAY MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 287. GERMANY IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 288. GERMANY IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 289. GERMANY IMMUNOASSAY MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 290. GERMANY IMMUNOASSAY MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
  • TABLE 291. GERMANY IMMUNOASSAY MARKET SIZE, BY REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 292. GERMANY IMMUNOASSAY MARKET SIZE, BY REAGENTS, 2025-2030 (USD MILLION)
  • TABLE 293. GERMANY IMMUNOASSAY MARKET SIZE, BY SAMPLE TYPES, 2018-2024 (USD MILLION)
  • TABLE 294. GERMANY IMMUNOASSAY MARKET SIZE, BY SAMPLE TYPES, 2025-2030 (USD MILLION)
  • TABLE 295. GERMANY IMMUNOASSAY MARKET SIZE, BY DETECTION MODES, 2018-2024 (USD MILLION)
  • TABLE 296. GERMANY IMMUNOASSAY MARKET SIZE, BY DETECTION MODES, 2025-2030 (USD MILLION)
  • TABLE 297. GERMANY IMMUNOASSAY MARKET SIZE, BY APPLICATION AREAS, 2018-2024 (USD MILLION)
  • TABLE 298. GERMANY IMMUNOASSAY MARKET SIZE, BY APPLICATION AREAS, 2025-2030 (USD MILLION)
  • TABLE 299. GERMANY IMMUNOASSAY MARKET SIZE, BY TOXICOLOGY, 2018-2024 (USD MILLION)
  • TABLE 300. GERMANY IMMUNOASSAY MARKET SIZE, BY TOXICOLOGY, 2025-2030 (USD MILLION)
  • TABLE 301. GERMANY IMMUNOASSAY MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 302. GERMANY IMMUNOASSAY MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 303. GERMANY IMMUNOASSAY MARKET SIZE, BY DEPLOYMENT TYPES, 2018-2024 (USD MILLION)
  • TABLE 304. GERMANY IMMUNOASSAY MARKET SIZE, BY DEPLOYMENT TYPES, 2025-2030 (USD MILLION)
  • TABLE 305. FRANCE IMMUNOASSAY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 306. FRANCE IMMUNOASSAY MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 307. FRANCE IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 308. FRANCE IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 309. FRANCE IMMUNOASSAY MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 310. FRANCE IMMUNOASSAY MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
  • TABLE 311. FRANCE IMMUNOASSAY MARKET SIZE, BY REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 312. FRANCE IMMUNOASSAY MARKET SIZE, BY REAGENTS, 2025-2030 (USD MILLION)
  • TABLE 313. FRANCE IMMUNOASSAY MARKET SIZE, BY SAMPLE TYPES, 2018-2024 (USD MILLION)
  • TABLE 314. FRANCE IMMUNOASSAY MARKET SIZE, BY SAMPLE TYPES, 2025-2030 (USD MILLION)
  • TABLE 315. FRANCE IMMUNOASSAY MARKET SIZE, BY DETECTION MODES, 2018-2024 (USD MILLION)
  • TABLE 316. FRANCE IMMUNOASSAY MARKET SIZE, BY DETECTION MODES, 2025-2030 (USD MILLION)
  • TABLE 317. FRANCE IMMUNOASSAY MARKET SIZE, BY APPLICATION AREAS, 2018-2024 (USD MILLION)
  • TABLE 318. FRANCE IMMUNOASSAY MARKET SIZE, BY APPLICATION AREAS, 2025-2030 (USD MILLION)
  • TABLE 319. FRANCE IMMUNOASSAY MARKET SIZE, BY TOXICOLOGY, 2018-2024 (USD MILLION)
  • TABLE 320. FRANCE IMMUNOASSAY MARKET SIZE, BY TOXICOLOGY, 2025-2030 (USD MILLION)
  • TABLE 321. FRANCE IMMUNOASSAY MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 322. FRANCE IMMUNOASSAY MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 323. FRANCE IMMUNOASSAY MARKET SIZE, BY DEPLOYMENT TYPES, 2018-2024 (USD MILLION)
  • TABLE 324. FRANCE IMMUNOASSAY MARKET SIZE, BY DEPLOYMENT TYPES, 2025-2030 (USD MILLION)
  • TABLE 325. RUSSIA IMMUNOASSAY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 326. RUSSIA IMMUNOASSAY MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 327. RUSSIA IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 328. RUSSIA IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 329. RUSSIA IMMUNOASSAY MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 330. RUSSIA IMMUNOASSAY MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
  • TABLE 331. RUSSIA IMMUNOASSAY MARKET SIZE, BY REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 332. RUSSIA IMMUNOASSAY MARKET SIZE, BY REAGENTS, 2025-2030 (USD MILLION)
  • TABLE 333. RUSSIA IMMUNOASSAY MARKET SIZE, BY SAMPLE TYPES, 2018-2024 (USD MILLION)
  • TABLE 334. RUSSIA IMMUNOASSAY MARKET SIZE, BY SAMPLE TYPES, 2025-2030 (USD MILLION)
  • TABLE 335. RUSSIA IMMUNOASSAY MARKET SIZE, BY DETECTION MODES, 2018-2024 (USD MILLION)
  • TABLE 336. RUSSIA IMMUNOASSAY MARKET SIZE, BY DETECTION MODES, 2025-2030 (USD MILLION)
  • TABLE 337. RUSSIA IMMUNOASSAY MARKET SIZE, BY APPLICATION AREAS, 2018-2024 (USD MILLION)
  • TABLE 338. RUSSIA IMMUNOASSAY MARKET SIZE, BY APPLICATION AREAS, 2025-2030 (USD MILLION)
  • TABLE 339. RUSSIA IMMUNOASSAY MARKET SIZE, BY TOXICOLOGY, 2018-2024 (USD MILLION)
  • TABLE 340. RUSSIA IMMUNOASSAY MARKET SIZE, BY TOXICOLOGY, 2025-2030 (USD MILLION)
  • TABLE 341. RUSSIA IMMUNOASSAY MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 342. RUSSIA IMMUNOASSAY MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 343. RUSSIA IMMUNOASSAY MARKET SIZE, BY DEPLOYMENT TYPES, 2018-2024 (USD MILLION)
  • TABLE 344. RUSSIA IMMUNOASSAY MARKET SIZE, BY DEPLOYMENT TYPES, 2025-2030 (USD MILLION)
  • TABLE 345. ITALY IMMUNOASSAY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 346. ITALY IMMUNOASSAY MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 347. ITALY IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 348. ITALY IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 349. ITALY IMMUNOASSAY MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 350. ITALY IMMUNOASSAY MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
  • TABLE 351. ITALY IMMUNOASSAY MARKET SIZE, BY REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 352. ITALY IMMUNOASSAY MARKET SIZE, BY REAGENTS, 2025-2030 (USD MILLION)
  • TABLE 353. ITALY IMMUNOASSAY MARKET SIZE, BY SAMPLE TYPES, 2018-2024 (USD MILLION)
  • TABLE 354. ITALY IMMUNOASSAY MARKET SIZE, BY SAMPLE TYPES, 2025-2030 (USD MILLION)
  • TABLE 355. ITALY IMMUNOASSAY MARKET SIZE, BY DETECTION MODES, 2018-2024 (USD MILLION)
  • TABLE 356. ITALY IMMUNOASSAY MARKET SIZE, BY DETECTION MODES, 2025-2030 (USD MILLION)
  • TABLE 357. ITALY IMMUNOASSAY MARKET SIZE, BY APPLICATION AREAS, 2018-2024 (USD MILLION)
  • TABLE 358. ITALY IMMUNOASSAY MARKET SIZE, BY APPLICATION AREAS, 2025-2030 (USD MILLION)
  • TABLE 359. ITALY IMMUNOASSAY MARKET SIZE, BY TOXICOLOGY, 2018-2024 (USD MILLION)
  • TABLE 360. ITALY IMMUNOASSAY MARKET SIZE, BY TOXICOLOGY, 2025-2030 (USD MILLION)
  • TABLE 361. ITALY IMMUNOASSAY MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 362. ITALY IMMUNOASSAY MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 363. ITALY IMMUNOASSAY MARKET SIZE, BY DEPLOYMENT TYPES, 2018-2024 (USD MILLION)
  • TABLE 364. ITALY IMMUNOASSAY MARKET SIZE, BY DEPLOYMENT TYPES, 2025-2030 (USD MILLION)
  • TABLE 365. SPAIN IMMUNOASSAY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 366. SPAIN IMMUNOASSAY MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 367. SPAIN IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 368. SPAIN IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 369. SPAIN IMMUNOASSAY MARKET SIZE, BY INSTRUMENTS, 2018-2